- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447053
Sequential Belimumab and T-cell Based Therapy in SLE
June 19, 2023 updated by: National University Hospital, Singapore
Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study
Systemic lupus erythematosus (SLE) is a disease in which the immune system (the bodily system that fights infection) attacks the body's own cells and tissues, causing inflammation and organ damage if not promptly and appropriately managed.
Autoantibodies (specific proteins produced by the immune system which participate in attacking self tissues and organs) are the hallmarks of SLE which are produced by a specific type of white blood cells called B cells.
Belimumab (Benlysta®) is a monoclonal antibody against the B cells by blocking the action of BLyS, a protein that prolongs the longevity and enhances the functions of B cells and is found to be elevated in patients with SLE, was approved by the FDA to treat patients with SLE.
This study aims to study the effects of Belimumab on T cells, another specific type of white blood cells which also play a crucial role in SLE, in patients with SLE.
In this trial, 80 adult patients with SLE will be recruited, 40 of them will be assigned to receive intravenous (IV) Belimumab with standard of care therapy (SOC), and 40 to receive SOC only.
After 48 weeks of exposure to Belimumab + SOC and SOC alone, the phenotype and functions of T cells will be studied and compared.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anselm Mak
- Phone Number: +6567722598
- Email: mdcam@nsu.edu.sg
Study Contact Backup
- Name: Nien Yee Kow
- Phone Number: +6566015194
- Email: mdckown@nus.edu.sg
Study Locations
-
-
-
SIngapore, Singapore
- Recruiting
- National University Hospital
-
Contact:
- Anselm Mak
- Phone Number: +6567722598
- Email: mdcam@nus.edu.sg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 21
- Able to understand the details of the trial and willing to give written informed consent and comply with the requirements of the study protocol.
- Patients who fulfill the classification criteria (SLICC 2012 or ACR 1997) for SLE and have active disease (SELENA-SLEDAI ≥ 6).
- Patients whose sera are positive for ANA (titre ≥ 1:80) or anti-dsDNA (>100U/L based on NUH standard laboratory cut-off).
- Patients who are on stable dose of prednisolone (0-40mg/day) and/or non-steroidal anti-inflammatory, antimalarial or immunosuppressive drugs for at least 30 days before first study dose.
- Females of child-bearing potential and non-sterilized males with female partners of child-bearing potential may participate this trial only if they use a reliable means of contraception.
- Females of child-bearing potential must have a negative serum pregnancy test within three weeks prior to baseline.
Exclusion Criteria:
- They have severe active nephritis and/or active CNS lupus and/or other autoimmune diseases e.g. RA, mixed connective tissue disease, scleroderma, dermatomyositis and polymyositis.
- They are pregnant.
- They have had previous treatment with any B-cell and T-cell targeted biologic therapy, intravenous (IV) cyclophosphamide within 6 months of enrolment, intravenous immunoglobulins or prednisolone (>100mg/day) within 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Belimumab + SOC
Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
|
Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
|
No Intervention: SOC only
Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparing the ratio of Treg/Teff in Belimumab + SOC arm with SOC-only arm
Time Frame: Baseline, week 4, week 12, week 24, week 36, week 48 and week 60
|
The enumeration of T-cell subsets by multi-color flow cytometry including Th1 (CD4+Tbet+), Th2 (CD4+GATA3+), Th17 (CD4+RoRgamat+) and Treg (CD4+CD25+FoxP3+) cells, as well as CD19+CD20+ B cells after staining with respective fluorescent-conjugated antibodies.
|
Baseline, week 4, week 12, week 24, week 36, week 48 and week 60
|
Identifying and comparing the TCR sequence of the variable regions (CDR1, CDR2 and CDR3) and their RNA expression profile before and after 48 weeks of Belimumab therapy
Time Frame: up to week 48
|
TCR sequencing and RNA expression with the use of the state-of-the-art 10x Genomic nano-droplet technology.
|
up to week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To compare the numeric difference in other T cell subsets (Th1, Th2 and Th17) between the 2 arms
Time Frame: Baseline, week 4, week 12, week 24, week 36, week 48 and week 60
|
The enumeration of T-cell subsets by multi-color flow cytometry.
|
Baseline, week 4, week 12, week 24, week 36, week 48 and week 60
|
To compare the potential improvement of cognitive function between the 2 arms
Time Frame: Baseline and week 52
|
The use of the computerized Automated Neuropsychological Assessment Matrix (ANAM) which serves as an initial screening tool to pick up subtle cognitive dysfunction in healthy populations and serial assessments to track the progress of cognitive dysfunction in SLE patients over time.
|
Baseline and week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Anselm Mak, National University Hospital, Singapore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2021
Primary Completion (Estimated)
May 20, 2025
Study Completion (Estimated)
May 20, 2025
Study Registration Dates
First Submitted
June 23, 2020
First Submitted That Met QC Criteria
June 24, 2020
First Posted (Actual)
June 25, 2020
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 19, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10743-SUBTLE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Belimumab Injection [Benlysta]
-
University Health Network, TorontoGlaxoSmithKlineNot yet recruitingAutoimmune Hepatitis
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineNo longer availableRheumatoid ArthritisUnited States
-
Oklahoma Medical Research FoundationGlaxoSmithKlineUnknownSystemic Lupus ErythematosusUnited States
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States
-
Leiden University Medical CenterGlaxoSmithKline; Dutch Kidney FoundationRecruitingLupus Erythematosus, SystemicNetherlands
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States
-
Human Genome Sciences Inc.CompletedSystemic Lupus ErythematosusUnited States
-
Human Genome Sciences Inc.CompletedArthritis, RheumatoidUnited States
-
GlaxoSmithKlineActive, not recruitingSystemic Lupus ErythematosusUnited States, France, Italy, Spain, Israel, Germany, Belgium, Sweden, Canada, Slovakia, Austria, Portugal, Argentina